Related Experiment Video

Updated: Dec 25, 2025

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

7.8K

Variations of circulating miRNA in paediatric patients with Heart Failure supported with Ventricular Assist Device: a

Rosetta Ragusa1,2, Arianna Di Molfetta3, Romina D'Aurizio4

  • 1Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.

Scientific Reports
|April 5, 2020
PubMed

Insights

Circulating microRNAs (c-miRNAs) in pediatric heart failure (HF) children changed after 30 days of ventricular assist device (VAD) treatment, potentially indicating a pro-thrombotic state. Six c-miRNAs involved in hemostasis were identified.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pediatric Cardiology

Background:

  • Circulating microRNAs (c-miRNAs) show potential as biomarkers for heart failure (HF) diagnosis and prognosis.
  • Limited research exists on c-miRNA profiles in pediatric HF patients, particularly those undergoing ventricular assist device (VAD) implantation.

Purpose of the Study:

  • To investigate the c-miRNA profile in children with HF.
  • To assess the impact of VAD implantation on c-miRNA levels.
  • To validate potential c-miRNA targets in vitro.

Main Methods:

  • Serum c-miRNA profiling using Next-Generation Sequencing (NGS) before and after VAD implantation.
  • Real-time PCR validation of differentially expressed c-miRNAs at multiple time points post-VAD.
  • In vitro miRNA mimic transfection in HepG2 cells to validate miRNA-target interactions.

Main Results:

  • Thirteen c-miRNAs showed altered levels 30 days post-VAD compared to pre-VAD levels; six were confirmed by Real-Time PCR.
  • Validated c-miRNAs target genes involved in the hemostatic process.
  • In vitro studies confirmed hsa-miR-409-3p down-regulates coagulation factors F7 and F2, and all patients experienced thrombotic events.

Conclusions:

  • VAD treatment in pediatric HF patients alters the levels of six c-miRNAs regulating hemostatic events within 30 days.
  • A decrease in c-miR-409-3p, targeting F7 and F2, may indicate a pro-thrombotic state post-VAD implantation.
  • These findings highlight potential c-miRNA biomarkers for monitoring thrombotic risk in pediatric VAD patients.

More Related Videos

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.6K
Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization08:22

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

8.5K

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
343
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
594
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
230
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
186
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
161
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
372